We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AIM ImmunoTech Inc. (AIM - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AIM ImmunoTech Inc. is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AIM ImmunoTech Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for AIM's full-year earnings has moved 3.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AIM has gained about 7.1% so far this year. In comparison, Medical companies have returned an average of 7.1%.
One other Medical stock that has outperformed the sector so far this year is Cullinan Therapeutics (CGEM - Free Report) . The stock is up 19.2% year-to-date.
The consensus estimate for Cullinan Therapeutics' current year EPS has increased 10% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AIM ImmunoTech Inc. belongs to the Medical - Drugs industry, which includes 141 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, stocks in this group have gained 3.5% this year, meaning that AIM is performing better in terms of year-to-date returns.
Cullinan Therapeutics, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 452-stock industry is ranked #94. The industry has moved +22.9% so far this year.
Investors with an interest in Medical stocks should continue to track AIM ImmunoTech Inc. and Cullinan Therapeutics. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AIM ImmunoTech Inc. (AIM - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AIM ImmunoTech Inc. is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AIM ImmunoTech Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for AIM's full-year earnings has moved 3.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AIM has gained about 7.1% so far this year. In comparison, Medical companies have returned an average of 7.1%.
One other Medical stock that has outperformed the sector so far this year is Cullinan Therapeutics (CGEM - Free Report) . The stock is up 19.2% year-to-date.
The consensus estimate for Cullinan Therapeutics' current year EPS has increased 10% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AIM ImmunoTech Inc. belongs to the Medical - Drugs industry, which includes 141 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, stocks in this group have gained 3.5% this year, meaning that AIM is performing better in terms of year-to-date returns.
Cullinan Therapeutics, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 452-stock industry is ranked #94. The industry has moved +22.9% so far this year.
Investors with an interest in Medical stocks should continue to track AIM ImmunoTech Inc. and Cullinan Therapeutics. These stocks will be looking to continue their solid performance.